By Markus Gores, Vice President, EMEA Thought Leadership, IQVIA; Tom Woods, Consultant, EMEA Thought Leadership, IQVIA; and Michele Cimmino, Director Sales and Account Management, IQVIA Biotech
In the realm of biomedical innovation, emerging biopharma companies (EBPs) have taken on an increasingly prominent role. In the past decade, these companies have embraced a new strategy of retaining ownership of their products and independently pursuing filing and commercialization.
While the U.S. market remains the primary focus for most EBPs, it is essential for them to broaden their horizons to maximize product value. Europe, as the second-largest pharmaceutical market globally, presents a compelling next step.
To take a closer look at the possibilities and challenges for EBPs looking to commercialize in Europe, the authors take a look at the crucial choices these companies must make to achieve success in this endeavor.